Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

LymphomaMultiple Myeloma (MM)
Do you want to read an article? Please log in or register.